Company intelligence / Profile preview

BioStratum Inc.

Durham, North Carolina, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~7
Development stage: Dissolved

Overview

BioStratum has pioneered research into basal lamina-targeted therapies for kidney disease, cancer, autoimmune diseases, and diabetes complications. Its pipeline includes several preclinical programs targeting metabolic and renal indications. The company has made significant scientific contributions but does not appear to have advanced any drug candidates beyond preclinical development as of the latest public information.

Therapeutic areas: OncologyImmunologyEndocrinologyNephrology
Modalities: Small molecule drugsChemical drugsBiological products
Industry: Biotech

Drug pipeline

2 assets

BioStratum INSR program

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioStratum Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioStratum Inc..

Explore the full profile